The University of Exeter was awarded a $962,486 delivery order contract by the National Institute on Aging (NIA) to conduct a clinical evaluation of a phenserine tartrate extended-controlled release tablet (ECRT) formulation. The contract, which has a period of performance ending on January 31, 2026, is for services related to evaluating the efficacy of the investigational treatment for early mild Alzheimer's disease and mild to moderate traumatic brain injury. The contract is a cost-no-fee arrangement and was not set aside for any specific business category. The University of Exeter, a public research university in the United Kingdom, has previously collaborated with the NIA on Alzheimer's disease and neurodegenerative research, leveraging its expertise in areas like brain imaging, cognitive assessments, and biomarker analysis. This contract is part of a larger $1,988,692 indefinite delivery vehicle (IDV) awarded to the university in February 2024, which allows the NIA to issue task orders for clinical evaluation services over a 30-month period.
Generated 1/22/25, 9:11 AM